PMID- 33300377
OWN - NLM
STAT- MEDLINE
DCOM- 20211115
LR  - 20211115
IS  - 1477-0903 (Electronic)
IS  - 0960-3271 (Linking)
VI  - 40
IP  - 6
DP  - 2021 Jun
TI  - LncRNA PART1 promotes lung squamous cell carcinoma progression via 
      miR-185-5p/Six1 axis.
PG  - 960-976
LID - 10.1177/0960327120979032 [doi]
AB  - Dysregulation of the long non-coding RNA prostate androgen regulated transcript 1 
      (lncRNA PART1) is involved in the tumorigenesis of various cancers. However, 
      little is known about its function and molecular mechanism in the development of 
      lung squamous cell carcinoma (LSCC). In this study, we examined the expression of 
      PART1 in LSCC clinical tissue samples and cell lines, and gain- and 
      loss-of-function experiments were performed to explore the function of PART1 in 
      LSCC proliferation, invasion and migration. We found that PART1 was overexpressed 
      in both LSCC tissues and cell lines. Functional studies revealed that PART1 
      knockdown significantly suppressed cell proliferation, invasion and migration but 
      enhanced apoptosis in LSCC cells, whereas overexpression of PART1 showed the 
      opposite results. Mechanistically, we identified that PART1 acted as a sponge of 
      miR-185-5p, and sineoculis homeobox homolog 1 (Six1) was a direct downstream 
      target of miR-185-5p. Moreover, restoration of miR-185-5p or silencing of Six1 
      partially abolished the oncogenic effect of PART1 in LSCC cells. Clinically, The 
      areas under the receiver operating characteristic (ROC) curve of PART1, 
      miR-185-5p, and Six1 were 0.7857, 0.7332, 0.8112, respectively. Notably, high 
      PART1, low miR-185-5p, and high Six1 expressions were significantly associated 
      with severe clinical parameters and were the independent risk factors for poor 
      prognosis of LSCC patients. Thus, we concluded that the PART1/miR-185-5p/Six1 
      axis might serve as a novel biomarker for the diagnosis and treatment of LSCC.
FAU - Cao, Y
AU  - Cao Y
AD  - Department of Thoracic Surgery, 159431Shaanxi Provincial People's Hospital, 
      Xi'an, Shaanxi, China.
FAU - Zhang, R
AU  - Zhang R
AD  - Department of Thoracic Surgery, 159431Shaanxi Provincial People's Hospital, 
      Xi'an, Shaanxi, China.
FAU - Luo, X
AU  - Luo X
AD  - Department of Thoracic Surgery, 159431Shaanxi Provincial People's Hospital, 
      Xi'an, Shaanxi, China.
FAU - Yang, Y
AU  - Yang Y
AUID- ORCID: 0000-0003-3167-3171
AD  - Department of Thoracic Surgery, 159431Shaanxi Provincial People's Hospital, 
      Xi'an, Shaanxi, China.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/*physiopathology
MH  - Carcinoma, Squamous Cell/*genetics/*physiopathology
MH  - Cell Line, Tumor/metabolism
MH  - China
MH  - Disease Progression
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/genetics/physiopathology
MH  - Neoplasm Proteins/*genetics/*metabolism
MH  - RNA, Long Noncoding/*genetics
OTO - NOTNLM
OT  - Lung squamous cell carcinoma
OT  - Six1
OT  - lncRNA PART1
OT  - miR-185-5p
EDAT- 2020/12/11 06:00
MHDA- 2021/11/16 06:00
CRDT- 2020/12/10 08:37
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/11/16 06:00 [medline]
PHST- 2020/12/10 08:37 [entrez]
AID - 10.1177/0960327120979032 [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 2021 Jun;40(6):960-976. doi: 10.1177/0960327120979032. Epub 2020 
      Dec 10.